Vaccinology

Morrow, John

doi:10.1002/9781118345313

Cited by 9 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The new types of vaccines are composed of injections into humans a snippet of nucleic acid driven by making of proteins, acting as a guide for enzymes involved in replication and repair process. [5][6][7][8]…”

Section: Vaccinology Developmentsmentioning

confidence: 99%

See 1 more Smart Citation

CRISPR Therapeutics: New Emerging Developments and Clinical Applications

Aziz-Andersen

2021

J. Drug Delivery Ther.

View full text Add to dashboard Cite

CRISPR gene editing is a genetic engineering technique applied in clinical applications in which the genomes of living organisms may be modified. It is based on the principles of the CRISPR-Cas9 antiviral defense system. It is based on delivering the Cas9 nuclease complexed with a synthetic guide RNA into a living organism cell and that organisms’s genome can be “cut” and –“paste” at a desired location, allowing existing genes to be modified for desired outcome (i.e., CRISPR for Precision Medicine). CRISPR gene editing harnesses the natural defense mechanisms of some bacteria to cut human DNA strands. Then the DNA strand either heals itself or injects a new piece of DNA to mend the gap. Studies have been reported in Lung Cancer diagnosis and treatments. CRISPR-based engineering techniques have been developed for T Cells and Stem cells applications (i.e. Gene Corrections in Hematopoietic Stem Cells for the Treatment of Blood and Immune System Diseases). Even though earlier CRISPR methodologies were used for performing simple DNA edits, recent applications include the ability to delete genes or insert genes, and edit regulatory regions in a wide range of cell types. The role of CRISPR in human therapeutics is currently focused on utilizing CRISPR techniques to perform either in vivo editing of human cells–everything from the head, eye all the way to neurons and liver cells--or performing ex vivo therapies. The FDA’s new genomic CRISPR technology based products approval process begins with review and evaluation of preclinical studies in order to establish and characterize the proposed product’s safety profile. New genomic products must be shown to be safe and effective for the FDA approval process. The sponsor of the new genomic product must show that the product is safe and effective in human subjects.1

show abstract

Section: Vaccinology Developmentsmentioning

confidence: 99%

“…These developments facilitated use of genetic based vaccines providing blood tests results indicating generation of neutralizing antibodies to fight the coronavirus. [5][6][7][8]…”

Section: B Nucleic Acid Based Technologiesmentioning

confidence: 99%

CRISPR Therapeutics: New Emerging Developments and Clinical Applications

Aziz-Andersen

2021

J. Drug Delivery Ther.

View full text Add to dashboard Cite

show abstract

Role of Microbes in the Pharmaceutical Industry

Chunduri¹,

Donthula²,

Jahanavi³

et al. 2022

Role of Microbes in Industrial Products and Processes

View full text Add to dashboard Cite

Targeted immunomodulation using antigen‐conjugated nanoparticles

McCarthy

Hunter

Chackerian

et al. 2014

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

The growing prevalence of nanotechnology in the fields of biology, medicine and the pharmaceutical industry is confounded by the relatively small amount of data on the impact of these materials on the immune system. In addition to concerns surrounding the potential toxicity of nanoparticle (NP)-based delivery systems, there is also a demand for a better understanding of the mechanisms governing interactions of NPs with the immune system. Nanoparticles can be tailored to suppress, enhance, or subvert recognition by the immune system. This “targeted immunomodulation” can be achieved by delivery of unmodified particles, or by modifying particles to deliver drugs, proteins/peptides or genes to a specific site. In order to elicit the desired, beneficial immune response, considerations should be made at every step of the design process: the NP platform itself, ligands and other modifiers, the delivery route, and the immune cells that will encounter the conjugated NPs can all impact host immune responses.

show abstract

Vaccinology

Cited by 9 publications

References 0 publications

CRISPR Therapeutics: New Emerging Developments and Clinical Applications

CRISPR Therapeutics: New Emerging Developments and Clinical Applications

Role of Microbes in the Pharmaceutical Industry

Targeted immunomodulation using antigen‐conjugated nanoparticles

Contact Info

Product

Resources

About